Pace Leonardo, Nicolai Emanuele, Basso Luca, Garbino Nunzia, Soricelli Andrea, Salvatore Marco
Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana", Università degli Studi di Salerno, Fisciano, Italy.
IRCCS SDN, Naples, Italy.
Mol Imaging Biol. 2020 Aug;22(4):1111-1115. doi: 10.1007/s11307-020-01482-z.
Recently brown adipose tissue (BAT) activation has been proposed to have a possible role in breast cancer. The aim of this study was to evaluate BAT activation in patients with breast cancer and its relationship with molecular characteristics of tumor.
The study group comprised 79 patients with histologically proven ductal breast carcinoma (51 ± 13 years). Data on distribution, intensity (SUVmax), and total metabolic activity (TMA) of BAT were obtained from [F] FDG-PET/CT. Clinical and biochemical data were obtained from the database.
BAT activation was present in 12 of the 79 patients (15.2 %). Patients with BAT activation were younger and had a lower body mass index (BMI) (p < 0.05 and p < 0.0005, respectively) and showed less frequently metastasis (p < 0.05). No significant differences were found in estrogen receptor (ER), progesterone receptor (PgR), Ki67, grade, and in molecular subtypes. In patients younger than 55 years and with a BMI < 26, no significant differences were observed between patients with and without BAT activation. In the 12 patients with BAT activation, a significant inverse correlation was observed between TMA and BMI (r = - 0.64, p < 0.05). TMA and SUVmax were higher in grade 2 than in grade 3 patients. No significant differences were found in both TMA and SUVmax between patients with and without lymph node metastases. A significant difference in both TMA and SUVmax was observed among different molecular types, with luminal B patients showing higher values.
In conclusion, the present study suggests a relation between BAT activation and positive known prognostic factor in breast cancer, such as intermediate tumor grade and luminal B cancer type.
最近有人提出棕色脂肪组织(BAT)激活可能在乳腺癌中发挥作用。本研究的目的是评估乳腺癌患者的BAT激活情况及其与肿瘤分子特征的关系。
研究组包括79例经组织学证实的导管乳腺癌患者(51±13岁)。BAT的分布、强度(SUVmax)和总代谢活性(TMA)数据来自[F]FDG-PET/CT。临床和生化数据来自数据库。
79例患者中有12例(15.2%)存在BAT激活。BAT激活的患者更年轻,体重指数(BMI)更低(分别为p<0.05和p<0.0005),转移频率更低(p<0.05)。雌激素受体(ER)、孕激素受体(PgR)、Ki67、分级和分子亚型方面未发现显著差异。在年龄小于55岁且BMI<26的患者中,有BAT激活和无BAT激活的患者之间未观察到显著差异。在12例有BAT激活的患者中,TMA与BMI之间存在显著负相关(r=-0.64,p<0.05)。2级患者的TMA和SUVmax高于3级患者。有无淋巴结转移的患者在TMA和SUVmax方面均未发现显著差异。不同分子类型之间在TMA和SUVmax方面均观察到显著差异,管腔B型患者的值更高。
总之,本研究表明BAT激活与乳腺癌中已知的阳性预后因素之间存在关联,如肿瘤中级分级和管腔B型癌症。